Decreased paraoxonase 2 enzymatic activity in monocyte/macrophages cells. A comparative in vivo and in vitro study for diabetes

Aim: To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity. Methods: One hundred and eighteen patients with newly diagnosed uncomplicated type 2 diabetes mellitus were compared regarding clinical, biochemical and oxidat...

Full description

Saved in:
Bibliographic Details
Published inFree radical research Vol. 51; no. 6; pp. 604 - 615
Main Authors Lixandru, D., Alexandru, P., Mihai, A., Roşca, A., Ionescu-Tîrgovişte, C., Braşoveanu, L.I., Manuel-y-Keenoy, B.
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 03.06.2017
Subjects
Online AccessGet full text
ISSN1071-5762
1029-2470
1029-2470
DOI10.1080/10715762.2017.1344983

Cover

Abstract Aim: To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity. Methods: One hundred and eighteen patients with newly diagnosed uncomplicated type 2 diabetes mellitus were compared regarding clinical, biochemical and oxidative stress parameters with 80 healthy subjects. The capacity of the peripheral blood mononuclear cells (PBMNC) to release pro-oxidants and to neutralise them was determined by measuring the respiratory burst (RB) and the intracellular antioxidant enzyme PON2. In vitro experiments were conducted on a differentiated monocytes cell line (dU937) that was exposed to serum deprivation followed by addition of isolated lipoproteins (VLDL or LDL). Results: Paraoxonase 2 activity in Mo/Mᴓ was significantly lower in type 2 diabetes patients (0.042 ± 0.044 vs 0.165 ± 0.133U lactonase activity/mg protein in controls, p < .0005) and decreased in the obese in all groups. It was inversely correlated to parameters of adiposity (BMI and Waist Circumference), of glucose control (blood glucose, fructosamine and HbA 1c ) and insulin resistance (HOMA-IR). In multivariate regression models, 15-34% of the PON2 variance was explained by diabetes. The in vitro addition of VLDL normalised the RB of serum deprived dU937 cells, S− (to 82 ± 18% of the cells incubated with serum, S+) and PON2 activity (from 0.524 ± 0.061 in S − to 0.298 ± 0.048 U/mg protein). In contrast, when LDL was added, the RB remained lower (61 ± 12% of S+, p = .03) and PON2 higher (0.580 ± 0.030 U/mg protein, p = .003). Conclusions: The decrease in monocyte/macrophage PON2 enzymatic activity observed in type 2 diabetes cannot be totally explained by abdominal obesity and insulin resistance. The underlying molecular mechanisms need to be identified.
AbstractList To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity. One hundred and eighteen patients with newly diagnosed uncomplicated type 2 diabetes mellitus were compared regarding clinical, biochemical and oxidative stress parameters with 80 healthy subjects. The capacity of the peripheral blood mononuclear cells (PBMNC) to release pro-oxidants and to neutralise them was determined by measuring the respiratory burst (RB) and the intracellular antioxidant enzyme PON2. In vitro experiments were conducted on a differentiated monocytes cell line (dU937) that was exposed to serum deprivation followed by addition of isolated lipoproteins (VLDL or LDL). Paraoxonase 2 activity in Mo/Mᴓ was significantly lower in type 2 diabetes patients (0.042 ± 0.044 vs 0.165 ± 0.133U lactonase activity/mg protein in controls, p < .0005) and decreased in the obese in all groups. It was inversely correlated to parameters of adiposity (BMI and Waist Circumference), of glucose control (blood glucose, fructosamine and HbA ) and insulin resistance (HOMA-IR). In multivariate regression models, 15-34% of the PON2 variance was explained by diabetes. The in vitro addition of VLDL normalised the RB of serum deprived dU937 cells, S- (to 82 ± 18% of the cells incubated with serum, S+) and PON2 activity (from 0.524 ± 0.061 in S - to 0.298 ± 0.048 U/mg protein). In contrast, when LDL was added, the RB remained lower (61 ± 12% of S+, p = .03) and PON2 higher (0.580 ± 0.030 U/mg protein, p = .003). The decrease in monocyte/macrophage PON2 enzymatic activity observed in type 2 diabetes cannot be totally explained by abdominal obesity and insulin resistance. The underlying molecular mechanisms need to be identified.
Aim: To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity. Methods: One hundred and eighteen patients with newly diagnosed uncomplicated type 2 diabetes mellitus were compared regarding clinical, biochemical and oxidative stress parameters with 80 healthy subjects. The capacity of the peripheral blood mononuclear cells (PBMNC) to release pro-oxidants and to neutralise them was determined by measuring the respiratory burst (RB) and the intracellular antioxidant enzyme PON2. In vitro experiments were conducted on a differentiated monocytes cell line (dU937) that was exposed to serum deprivation followed by addition of isolated lipoproteins (VLDL or LDL). Results: Paraoxonase 2 activity in Mo/Mᴓ was significantly lower in type 2 diabetes patients (0.042 ± 0.044 vs 0.165 ± 0.133U lactonase activity/mg protein in controls, p < .0005) and decreased in the obese in all groups. It was inversely correlated to parameters of adiposity (BMI and Waist Circumference), of glucose control (blood glucose, fructosamine and HbA 1c ) and insulin resistance (HOMA-IR). In multivariate regression models, 15-34% of the PON2 variance was explained by diabetes. The in vitro addition of VLDL normalised the RB of serum deprived dU937 cells, S− (to 82 ± 18% of the cells incubated with serum, S+) and PON2 activity (from 0.524 ± 0.061 in S − to 0.298 ± 0.048 U/mg protein). In contrast, when LDL was added, the RB remained lower (61 ± 12% of S+, p = .03) and PON2 higher (0.580 ± 0.030 U/mg protein, p = .003). Conclusions: The decrease in monocyte/macrophage PON2 enzymatic activity observed in type 2 diabetes cannot be totally explained by abdominal obesity and insulin resistance. The underlying molecular mechanisms need to be identified.
To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity.AIMTo investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity.One hundred and eighteen patients with newly diagnosed uncomplicated type 2 diabetes mellitus were compared regarding clinical, biochemical and oxidative stress parameters with 80 healthy subjects. The capacity of the peripheral blood mononuclear cells (PBMNC) to release pro-oxidants and to neutralise them was determined by measuring the respiratory burst (RB) and the intracellular antioxidant enzyme PON2. In vitro experiments were conducted on a differentiated monocytes cell line (dU937) that was exposed to serum deprivation followed by addition of isolated lipoproteins (VLDL or LDL).METHODSOne hundred and eighteen patients with newly diagnosed uncomplicated type 2 diabetes mellitus were compared regarding clinical, biochemical and oxidative stress parameters with 80 healthy subjects. The capacity of the peripheral blood mononuclear cells (PBMNC) to release pro-oxidants and to neutralise them was determined by measuring the respiratory burst (RB) and the intracellular antioxidant enzyme PON2. In vitro experiments were conducted on a differentiated monocytes cell line (dU937) that was exposed to serum deprivation followed by addition of isolated lipoproteins (VLDL or LDL).Paraoxonase 2 activity in Mo/Mᴓ was significantly lower in type 2 diabetes patients (0.042 ± 0.044 vs 0.165 ± 0.133U lactonase activity/mg protein in controls, p < .0005) and decreased in the obese in all groups. It was inversely correlated to parameters of adiposity (BMI and Waist Circumference), of glucose control (blood glucose, fructosamine and HbA1c) and insulin resistance (HOMA-IR). In multivariate regression models, 15-34% of the PON2 variance was explained by diabetes. The in vitro addition of VLDL normalised the RB of serum deprived dU937 cells, S- (to 82 ± 18% of the cells incubated with serum, S+) and PON2 activity (from 0.524 ± 0.061 in S - to 0.298 ± 0.048 U/mg protein). In contrast, when LDL was added, the RB remained lower (61 ± 12% of S+, p = .03) and PON2 higher (0.580 ± 0.030 U/mg protein, p = .003).RESULTSParaoxonase 2 activity in Mo/Mᴓ was significantly lower in type 2 diabetes patients (0.042 ± 0.044 vs 0.165 ± 0.133U lactonase activity/mg protein in controls, p < .0005) and decreased in the obese in all groups. It was inversely correlated to parameters of adiposity (BMI and Waist Circumference), of glucose control (blood glucose, fructosamine and HbA1c) and insulin resistance (HOMA-IR). In multivariate regression models, 15-34% of the PON2 variance was explained by diabetes. The in vitro addition of VLDL normalised the RB of serum deprived dU937 cells, S- (to 82 ± 18% of the cells incubated with serum, S+) and PON2 activity (from 0.524 ± 0.061 in S - to 0.298 ± 0.048 U/mg protein). In contrast, when LDL was added, the RB remained lower (61 ± 12% of S+, p = .03) and PON2 higher (0.580 ± 0.030 U/mg protein, p = .003).The decrease in monocyte/macrophage PON2 enzymatic activity observed in type 2 diabetes cannot be totally explained by abdominal obesity and insulin resistance. The underlying molecular mechanisms need to be identified.CONCLUSIONSThe decrease in monocyte/macrophage PON2 enzymatic activity observed in type 2 diabetes cannot be totally explained by abdominal obesity and insulin resistance. The underlying molecular mechanisms need to be identified.
Author Ionescu-Tîrgovişte, C.
Alexandru, P.
Roşca, A.
Braşoveanu, L.I.
Lixandru, D.
Mihai, A.
Manuel-y-Keenoy, B.
Author_xml – sequence: 1
  givenname: D.
  surname: Lixandru
  fullname: Lixandru, D.
  email: daniela.lixandru@umfcd.ro
  organization: Department of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy
– sequence: 2
  givenname: P.
  surname: Alexandru
  fullname: Alexandru, P.
  organization: Department of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy
– sequence: 3
  givenname: A.
  surname: Mihai
  fullname: Mihai, A.
  organization: National Institute of Diabetes, Nutrition and Metabolic Disease "Prof. N. Paulescu"
– sequence: 4
  givenname: A.
  surname: Roşca
  fullname: Roşca, A.
  organization: University of Medicine and Pharmacy "Carol Davila"
– sequence: 5
  givenname: C.
  surname: Ionescu-Tîrgovişte
  fullname: Ionescu-Tîrgovişte, C.
  organization: National Institute of Diabetes, Nutrition and Metabolic Disease "Prof. N. Paulescu"
– sequence: 6
  givenname: L.I.
  surname: Braşoveanu
  fullname: Braşoveanu, L.I.
  organization: Center of Immunology, Romanian Academy
– sequence: 7
  givenname: B.
  surname: Manuel-y-Keenoy
  fullname: Manuel-y-Keenoy, B.
  organization: Department of Pharmacy, University of Antwerp
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28637359$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtv1DAUhS1URB_wE0BessnUj_gRsaEqtCBVYgNr68ZxwCixB9szJWz46ziamQ0LWPla-s6x7zmX6CzE4BB6ScmGEk2uKVFUKMk2jFC1obxtO82foAtKWNewVpGzdVa0WaFzdJnzd0IqJtQzdM605IqL7gL9fudscpDdgLeQIP6MoV4wwy78WmYo3mKwxe99WbAPeI4h2qW46xlsittv8NVlbN005Q2-wTbOq0nF3Qrv_T5iCMNhLiniXHbDgseY8OChd8Xl5-jpCFN2L47nFfpy9_7z7Yfm4dP9x9ubh8ZyKUvTU91xLqyzlsmR0k6pgaheKEaFGNq6lSVUdqCIdn1vey06TYAyKuXYSqn5FXp98N2m-GPncjGzz-vHIbi4y4Z2lEmimRIVfXVEd_3sBrNNfoa0mFNoFXhzAGoEOSc3GutL3TqGksBPhhKzVmROFZm1InOsqKrFX-rTA__TvT3ofKgBzvAY0zSYAssU05ggWJ8N_7fFH_nJp9Y
CitedBy_id crossref_primary_10_1016_j_lfs_2022_121147
crossref_primary_10_1016_j_lfs_2020_117397
crossref_primary_10_1007_s12038_021_00234_7
Cites_doi 10.1161/01.ATV.15.11.1812
10.1016/S0022-2275(20)40633-9
10.1093/clinchem/18.6.499
10.1038/28406
10.1016/j.freeradbiomed.2004.06.030
10.1038/362801a0
10.1097/00043798-199604000-00014
10.1210/jcem.85.8.6854
10.2337/diab.41.10.1301
10.1161/01.CIR.102.18.2180
10.1016/0021-9150(94)90085-X
10.2337/diab.7.3.194
10.1016/0003-2697(76)90527-3
10.1093/ajcn/59.4.795
10.1038/414813a
10.1016/0003-2697(79)90222-7
10.1038/sj.jhh.1000804
10.1371/journal.pone.0078241
10.2337/diabetes.50.12.2792
10.1038/cddis.2010.91
10.1016/j.atherosclerosis.2009.11.044
10.1016/S0006-291X(76)80299-9
10.1161/CIRCRESAHA.110.223545
10.1089/ars.2010.3430
10.1155/2012/342806
10.1016/S0889-8529(05)70324-8
10.1111/j.1742-4658.2010.07911.x
10.4103/2230-8210.111618
10.1016/S0022-3565(25)22750-1
10.3390/ijms151120290
10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
10.1046/j.1365-2362.2002.00977.x
10.1074/jbc.M004543200
10.1016/j.atherosclerosis.2007.01.007
10.1007/3-540-27661-0_9
10.1016/S0008-6363(03)00365-1
10.1210/jc.2003-031897
10.1016/S0022-2275(20)30125-5
10.1038/sj.ejcn.1602698
10.1007/BF00280883
10.2337/diab.37.6.832
10.2337/dc08-s247
10.1177/147323001204000235
10.1093/ajcn/75.4.767
10.1074/jbc.M506172200
10.1007/s00125-004-1525-1
10.1161/01.ATV.0000097769.47306.12
10.1007/978-1-60327-029-8_24
10.1159/000323096
ContentType Journal Article
Copyright 2017 Informa UK Limited, trading as Taylor & Francis Group 2017
Copyright_xml – notice: 2017 Informa UK Limited, trading as Taylor & Francis Group 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1080/10715762.2017.1344983
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1029-2470
EndPage 615
ExternalDocumentID 28637359
10_1080_10715762_2017_1344983
1344983
Genre Article
Journal Article
Comparative Study
GrantInformation_xml – fundername: CNCS
– fundername: UEFISCDI
  grantid: PN-II-ID-PCE-2011-3-0429
– fundername: University of Antwerp
  grantid: POSDRU/89/1.5/S/60746; POSDRU/107/1.5/S/82514
– fundername: European Social Fund
  grantid: POSDR/159/1.5/S/135760
GroupedDBID ---
00X
03L
0BK
0R~
29H
30N
36B
4.4
53G
5GY
A8Z
AAJMT
AALDU
AAMIU
AAPUL
AAQRR
ABCCY
ABDBF
ABFIM
ABJNI
ABLIJ
ABLKL
ABPAQ
ABXUL
ABXYU
ACGEJ
ACGFS
ACTIO
ACUHS
ADCVX
ADGTB
ADOPC
ADRBQ
ADXPE
AEISY
AENEX
AEOZL
AEPSL
AEYOC
AFKVX
AFOSN
AGDLA
AHDZW
AIJEM
AJWEG
AKBVH
AKOOK
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AQRUH
AWYRJ
BABNJ
BLEHA
CCCUG
CS3
DGEBU
DKSSO
DU5
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
EST
ESTFP
ESX
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
M4Z
MM.
O9-
P2P
RNANH
ROSJB
RTWRZ
SV3
TBQAZ
TDBHL
TFDNU
TFL
TFT
TFW
TQWBC
TTHFI
TUROJ
TUS
V1S
ZGOLN
~1N
AAGDL
AAHIA
AAYXX
AFRVT
AIYEW
CITATION
TASJS
.HR
5VS
AAGME
AALIY
AAOAP
AAPXX
ABFMO
ABJYH
ABTAA
ACBBU
ACDHJ
ACQMU
ADGTR
ADYSH
AFDYB
AFFNX
APNXG
AURDB
BFWEY
CAG
CGR
COF
CUY
CVF
CWRZV
ECM
EIF
HGUVV
JEPSP
LJTGL
M44
NPM
NUSFT
OWHGL
PCLFJ
RNS
Z0Y
ZXP
7X8
ID FETCH-LOGICAL-c366t-b189335cecc26f11977d07b572155d4457c0169a708ebbcb85980a12166f46683
ISSN 1071-5762
1029-2470
IngestDate Mon Sep 08 10:32:03 EDT 2025
Wed Feb 19 02:40:40 EST 2025
Wed Sep 10 04:58:48 EDT 2025
Thu Apr 24 22:58:59 EDT 2025
Wed Dec 25 09:04:28 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords paraoxonase 2
Monocytes/macrophages
type 2 diabetes
obesity
respiratory burst
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c366t-b189335cecc26f11977d07b572155d4457c0169a708ebbcb85980a12166f46683
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 28637359
PQID 1912608275
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_1912608275
informaworld_taylorfrancis_310_1080_10715762_2017_1344983
pubmed_primary_28637359
crossref_citationtrail_10_1080_10715762_2017_1344983
crossref_primary_10_1080_10715762_2017_1344983
PublicationCentury 2000
PublicationDate 2017-06-03
PublicationDateYYYYMMDD 2017-06-03
PublicationDate_xml – month: 06
  year: 2017
  text: 2017-06-03
  day: 03
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Free radical research
PublicationTitleAlternate Free Radic Res
PublicationYear 2017
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References CIT0030
CIT0031
CIT0034
CIT0033
Bacanu E (CIT0041) 2012; 60
Chateau MT (CIT0045) 1996; 13
CIT0036
CIT0035
CIT0038
CIT0037
Defacque H (CIT0016) 1994; 271
CIT0039
McEneny J (CIT0022) 2002; 43
Hor-Yue T (CIT0032) 2016
CIT0040
CIT0043
CIT0042
CIT0001
Mohanty P (CIT0010) 2002; 75
CIT0044
Gavella M (CIT0052) 2002; 28
CIT0003
CIT0047
CIT0002
CIT0046
CIT0049
CIT0004
CIT0048
CIT0007
CIT0006
CIT0009
CIT0008
CIT0050
CIT0051
CIT0053
CIT0012
CIT0011
CIT0014
CIT0013
CIT0015
CIT0018
CIT0017
CIT0019
CIT0021
CIT0023
Havel R (CIT0005) 1994; 59
Redgrave TG (CIT0020) 1979; 20
CIT0025
CIT0024
CIT0027
CIT0026
CIT0029
CIT0028
References_xml – ident: CIT0025
  doi: 10.1161/01.ATV.15.11.1812
– volume: 20
  start-page: 217
  year: 1979
  ident: CIT0020
  publication-title: J. Lipid Res
  doi: 10.1016/S0022-2275(20)40633-9
– ident: CIT0014
  doi: 10.1093/clinchem/18.6.499
– ident: CIT0012
  doi: 10.1038/28406
– volume: 28
  start-page: 391
  year: 2002
  ident: CIT0052
  publication-title: Diab Metab
– ident: CIT0031
  doi: 10.1016/j.freeradbiomed.2004.06.030
– ident: CIT0002
  doi: 10.1038/362801a0
– ident: CIT0004
  doi: 10.1097/00043798-199604000-00014
– ident: CIT0009
  doi: 10.1210/jcem.85.8.6854
– ident: CIT0011
  doi: 10.2337/diab.41.10.1301
– ident: CIT0003
  doi: 10.1161/01.CIR.102.18.2180
– ident: CIT0021
  doi: 10.1016/0021-9150(94)90085-X
– ident: CIT0001
  doi: 10.2337/diab.7.3.194
– ident: CIT0018
  doi: 10.1016/0003-2697(76)90527-3
– volume: 59
  start-page: 795
  year: 1994
  ident: CIT0005
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/59.4.795
– ident: CIT0006
  doi: 10.1038/414813a
– ident: CIT0024
  doi: 10.1016/0003-2697(79)90222-7
– ident: CIT0034
  doi: 10.1038/sj.jhh.1000804
– ident: CIT0029
  doi: 10.1371/journal.pone.0078241
– ident: CIT0035
  doi: 10.2337/diabetes.50.12.2792
– ident: CIT0043
  doi: 10.1038/cddis.2010.91
– ident: CIT0049
  doi: 10.1016/j.atherosclerosis.2009.11.044
– ident: CIT0017
  doi: 10.1016/S0006-291X(76)80299-9
– ident: CIT0033
  doi: 10.1161/CIRCRESAHA.110.223545
– ident: CIT0028
  doi: 10.1089/ars.2010.3430
– volume: 13
  start-page: 19
  year: 1996
  ident: CIT0045
  publication-title: FEMS Immunol Med Microbiol
– ident: CIT0042
  doi: 10.1155/2012/342806
– ident: CIT0007
  doi: 10.1016/S0889-8529(05)70324-8
– ident: CIT0039
  doi: 10.1111/j.1742-4658.2010.07911.x
– ident: CIT0044
  doi: 10.4103/2230-8210.111618
– volume: 271
  start-page: 193
  year: 1994
  ident: CIT0016
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)22750-1
– ident: CIT0037
  doi: 10.3390/ijms151120290
– ident: CIT0013
  doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
– ident: CIT0027
  doi: 10.1046/j.1365-2362.2002.00977.x
– ident: CIT0019
  doi: 10.1074/jbc.M004543200
– ident: CIT0050
  doi: 10.1016/j.atherosclerosis.2007.01.007
– start-page: 16:
  year: 2016
  ident: CIT0032
  publication-title: Oxid Med Cell Longev
– volume: 60
  start-page: 21
  year: 2012
  ident: CIT0041
  publication-title: Farmacia
– ident: CIT0030
  doi: 10.1007/3-540-27661-0_9
– ident: CIT0046
  doi: 10.1016/S0008-6363(03)00365-1
– ident: CIT0026
  doi: 10.1210/jc.2003-031897
– volume: 43
  start-page: 824
  year: 2002
  ident: CIT0022
  publication-title: J Lipid Res
  doi: 10.1016/S0022-2275(20)30125-5
– ident: CIT0023
  doi: 10.1038/sj.ejcn.1602698
– ident: CIT0015
  doi: 10.1007/BF00280883
– ident: CIT0008
  doi: 10.2337/diab.37.6.832
– ident: CIT0038
  doi: 10.2337/dc08-s247
– ident: CIT0040
  doi: 10.1177/147323001204000235
– volume: 75
  start-page: 767
  year: 2002
  ident: CIT0010
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/75.4.767
– ident: CIT0047
  doi: 10.1074/jbc.M506172200
– ident: CIT0036
  doi: 10.1007/s00125-004-1525-1
– ident: CIT0048
  doi: 10.1161/01.ATV.0000097769.47306.12
– ident: CIT0053
  doi: 10.1007/978-1-60327-029-8_24
– ident: CIT0051
  doi: 10.1159/000323096
SSID ssj0013457
Score 2.2041042
Snippet Aim: To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity. Methods: One...
To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity. One hundred and...
To investigate peripheral blood monocytes/macrophages (Mo/Mᴓ) paraoxonase 2 (PON2) in diabetes and the factors modulating its activity.AIMTo investigate...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 604
SubjectTerms Adipose Tissue - enzymology
Adipose Tissue - pathology
Adult
Alanine Transaminase - blood
Aryldialkylphosphatase - genetics
Aryldialkylphosphatase - metabolism
Aspartate Aminotransferases - blood
Blood Glucose - metabolism
Case-Control Studies
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Cholesterol, VLDL - blood
Cholesterol, VLDL - pharmacology
Diabetes Mellitus, Type 2 - enzymology
Diabetes Mellitus, Type 2 - genetics
Diabetes Mellitus, Type 2 - pathology
Female
gamma-Glutamyltransferase - blood
Glycated Hemoglobin A - metabolism
Humans
Insulin Resistance
Male
Middle Aged
Monocytes/macrophages
obesity
Obesity - enzymology
Obesity - genetics
Obesity - pathology
paraoxonase 2
Reactive Oxygen Species - metabolism
respiratory burst
Respiratory Burst - drug effects
Triglycerides - blood
type 2 diabetes
U937 Cells
Title Decreased paraoxonase 2 enzymatic activity in monocyte/macrophages cells. A comparative in vivo and in vitro study for diabetes
URI https://www.tandfonline.com/doi/abs/10.1080/10715762.2017.1344983
https://www.ncbi.nlm.nih.gov/pubmed/28637359
https://www.proquest.com/docview/1912608275
Volume 51
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbKJgEvCMat3GQk9jSlixNfkseqo6oQQwh1YuIlSlxHiwQJatOJ7YWfwl_lnNjJMjo0Li-WdWrXrs_XkxP7-DuEvIr9LA-iTHvIxYUF81IWp16I3FnSsFw3QTSH7-TsiL85FseDwY9e1NK6zkb6_Mp7Jf-iVZCBXvGW7F9otvtSEEAd9AslaBjKP9LxQePzrcBnRAbv6ht41SvcUDXl-ZmjYtUuO0RR7sG0Kn2G6fCmX1LM3HWSIsEDbt2vRmAgdI8IHJqfFqeV42aCer2sLBVtE5fY7tj2Xdvp0pi9ZWrPfRyHULfX_LbAazTLdWPiRh3K7O0aK37fiQ8LlyR73Ik-VLsTsRtPddqTu80K1kTW-WEHr_lG3pCe6QVnxxOtbTZOFuD5j00t0tprR1BbbBhfaRMZu-e4tNdENx4RNqYSR8PBMLhPjVjIeWwT6vzCvu0-uUG2A6UwDmB7PDv49PHioIo3ZLLd5NtLYpG_f-UQl9yfS-S4v3_FaVyd-V1yx72j0LEF3D0yMOUOuTVpUwPukJuHLiLjPvneYZD2MEgD2mGQthikRUlbDO73EEgtAumY9hCIjRGBFPBh64BA2iCQwq-hLQIfkKPp6_lk5rmkHp4Opay9jIGHHAoNpiOQOR5iq4WvMqHA9xQLDsupkSAoVX5kskxnkYgjP2UBkzLnUkbhQ7JVVqV5TKjgHBqweOEvcg6OemxCpYTk2ULFOk3NkPB2rRPtGO8x8crnhDli3FZFCaoocSoaklHX7aulfLmuQ9xXZFI3KM8twJPwmr4vW60noERc8LQ01XqVsJgFEhx0JYbkkYVDN50gkqEKRfzkP0Z-Sm5f_EOfka16uTbPwcGusxcO5D8BXtDH6w
linkProvider Library Specific Holdings
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BkSgXHgXK8jQS14Q4fsXHqlAt0N1TK_VmxY6jVkBSNdmK9sJfx-MkfSBVPfSSRIonicfj-LNn_A3AJ53ZOi-sS5CLCw80KakuE4bcWdLT2sUgmsVSzvf59wNxcGUvDIZV4hy6Hogi4r8aOzcuRk8hceGsaMDJuI-KqpQyznXB7sMDEbA7WjnLlpeeBB7ZPlEkQZlpF89Nj7k2Pl1jL70Zg8axaOcJuKkWQwjKz3TV29Sd_0fweLdqPoXHI1QlW4NtPYN7vtmA9e0pQ9wGPFyMjvnn8PdLhJ-drwiSibd_AsDvPMmJb87PIisswR0UmKiCHDUk2H7rznr_-XeJKcQOw0-tI-hD6FKyRdwlIzkWPj06bUmoxXDdn7QkcuKSoDMyLR2_gP2dr3vb82TM7ZA4JmWfWBqAEhMuWFAua_RlqipTVoQJqRAVD43mkCemVFnhrXW2ELrISppTKWsuZcFewlrTNv4VEMF5KEB1lVU1D3hNe6aUkNxWSruy9DPgU4saNxKfY_6NX4aO_KiTog0q2oyKnkF6IXY8MH_cJqCvmovp45JLPeRHMewW2Y-TbZnQiKjwsvHtqjNhPh2mnEWuxAw2B6O7-Jy8kEwxoV_f4c0fYH2-t9g1u9-WP97AI7wVI-HYW1jrT1b-XcBcvX0fO9U__TUbXQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9UwFG8UE-RFFD-4iloTXzfX9Wt9JMANfnDjgyS-NWvXRaJuhO0S4cV_3XO6DYSE8MDLtmQ923p6uv7ac_o7hLw3mavzwvkEubjwwJKSmTLhyJ2lAqt9DKI5WKj9Q_Hpu5yiCbsxrBLn0PVAFBH_1di5j6t6ioiDs2YAk3EbFdMp40KYgt8nDxTAE4zq49ni0pEgItkniiQoM23iuekxV4anK-SlN0PQOBTN14mbKjFEoPxMl71L_fk1fsc71fIxeTQCVbo9WNYTci80G-ThzpQfboOsHoxu-afk724En12oKFKJt38A3neB5jQ052eRE5bi_glMU0GPGgqW3_qzPnz4XWICsR_wS-soehC6lG5Tf8lHjoVPj05bCpUYrvuTlkZGXAoqo9PC8TNyON_7trOfjJkdEs-V6hPHACZx6cF-clWjJ1NXmXYSpqNSVgLazCNLTKmzIjjnXSFNkZUsZ0rVQqmCPycrTduETUKlEFCAmSqragFozQSutVTCVdr4sgwzIqYGtX6kPcfsG78sG9lRJ0VbVLQdFT0j6YXY8cD7cZuA-d9abB8XXOohO4rlt8i-m0zLQiOiwssmtMvOwmwaJpxFruWMvBhs7uJz8kJxzaV5eYc3vyWrX3fn9svHxedXZA3vxDA4vkVW-pNleA2Aq3dvYpf6B1vpGgE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+paraoxonase+2+enzymatic+activity+in+monocyte%2Fmacrophages+cells.+A+comparative+in+vivo+and+in+vitro+study+for+diabetes&rft.jtitle=Free+radical+research&rft.au=Lixandru%2C+D.&rft.au=Alexandru%2C+P.&rft.au=Mihai%2C+A.&rft.au=Ro%C5%9Fca%2C+A.&rft.date=2017-06-03&rft.pub=Taylor+%26+Francis&rft.issn=1071-5762&rft.eissn=1029-2470&rft.volume=51&rft.issue=6&rft.spage=604&rft.epage=615&rft_id=info:doi/10.1080%2F10715762.2017.1344983&rft.externalDocID=1344983
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1071-5762&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1071-5762&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1071-5762&client=summon